Pharmaxis (PXSLY) Stock Price, News & Analysis

Company Overview

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Key Stats

• Today's Range: $0.88 to $0.88
• 50-Day Range: $0.88 to $0.88
• 52-Week Range: $0.62 to $1.47
• Volume: N/A
• Average Volume: 1,000 shs
• Market Capitalization: $26.53 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PXSLY Stock Analysis - Frequently Asked Questions

How have PXSLY shares performed this year?

Pharmaxis' stock was trading at $0.88 on January 1st, 2025. Since then, PXSLY stock has increased by 0.0% and is now trading at $0.88.

How do I buy shares of Pharmaxis?

Shares of PXSLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PXSLY
• CIK: 1301357
• Web: www.pharmaxis.com.au
• Phone: 61-2-9454-7200
• Fax: N/A
• Employees: 69
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 2.82
• Current Ratio: 3.31
• Quick Ratio: 2.92

Sales & Book Value

• Annual Sales: $8.75 million
• Price / Sales: 3.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.04 per share
• Price / Book: 22.00

Miscellaneous

• Outstanding Shares: 30,150,000
• Free Float: N/A
• Market Cap: $26.53 million
• Optionable: Not Optionable
• Beta: 1.22